Hematologic Malignancy
High Grade B-Cell Lymphoma
CI-CAN-00007803HGBLExplore in graph →
Hematologic84 active trials2 approved drugs
- NCIt
- C138211
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00007803HGBLExplore in graph →
Clinical trials
142 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (16)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03656835 | Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma | active not recruiting | N/A | 73 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06693830 | ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL | recruiting | N/A | 40 | Hua-Jay J Cherng, MDOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT06004167 | Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) | completed | N/A | 10 | Massachusetts General HospitalOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT04503538 | Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity | withdrawn | N/A | 0 | Wake Forest University Health SciencesOTHER | 0 | Oct 23, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Aug 6, 2026source: clinicaltrials